Acrivon Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Acrivon Therapeutics has a total shareholder equity of $108.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $120.5M and $12.5M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$109.98m |
| Equity | US$107.98m |
| Total liabilities | US$12.54m |
| Total assets | US$120.52m |
Recent financial health updates
Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29
Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Recent updates
Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Financial Position Analysis
Short Term Liabilities: ACRV's short term assets ($112.1M) exceed its short term liabilities ($9.0M).
Long Term Liabilities: ACRV's short term assets ($112.1M) exceed its long term liabilities ($3.5M).
Debt to Equity History and Analysis
Debt Level: ACRV is debt free.
Reducing Debt: ACRV had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ACRV has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ACRV has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 49.6% each year.